Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus CALOMIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus CALOMIST.
ACUVUE THERAVISION WITH KETOTIFEN vs CALOMIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Calomist (calcium gluconate) provides calcium ions to stabilize cardiac cell membranes, correct hypocalcemia, and antagonize hyperkalemia-induced cardiotoxicity.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
Mist inhalation: 1-2 actuations (100-200 mcg) delivered orally via nebulizer every 6 hours as needed for bronchospasm; maximum 12 actuations per day.
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Terminal elimination half-life: 4-6 hours; prolonged in renal impairment (up to 20 hours in anuria)
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Renal: 90% unchanged; biliary/fecal: 10%
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Mast Cell Stabilizer